[Cl-].O[NH3+:3].[C:4](=[O:7])([O-])[OH:5].[Na+].[O:9]=[C:10]1[C:15]([CH2:16][C:17]2[CH:22]=[CH:21][C:20]([C:23]3[C:24]([C:29]#[N:30])=[CH:25][CH:26]=[CH:27][CH:28]=3)=[CH:19][CH:18]=2)=[C:14]([CH2:31][CH2:32][CH3:33])[N:13]2[N:34]=[CH:35][N:36]=[C:12]2[N:11]1[CH:37]1[CH2:42][CH2:41][N:40]([CH:43]2[CH2:48][CH2:47][O:46][CH2:45][CH2:44]2)[CH2:39][CH2:38]1>CS(C)=O.C(OCC)(=O)C>[O:7]=[C:4]1[O:5][N:3]=[C:29]([C:24]2[CH:25]=[CH:26][CH:27]=[CH:28][C:23]=2[C:20]2[CH:19]=[CH:18][C:17]([CH2:16][C:15]3[C:10](=[O:9])[N:11]([CH:37]4[CH2:42][CH2:41][N:40]([CH:43]5[CH2:48][CH2:47][O:46][CH2:45][CH2:44]5)[CH2:39][CH2:38]4)[C:12]4[N:13]([N:34]=[CH:35][N:36]=4)[C:14]=3[CH2:31][CH2:32][CH3:33])=[CH:22][CH:21]=2)[NH:30]1A mixture of hydroxylammonium chloride (615 mg), sodium hydrogen carbonate (911 mg) and dimethyl sulfoxide (6 mL) was stirred at 60° C. for 30 min, a solution of 4′-({5-oxo-7-propyl-4-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-4,5-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-6-yl}methyl)biphenyl-2-carbonitrile (317 mg) in dimethyl sulfoxide (3 mL) was added, and the mixture was stirred at 90° C. for 16 hr. The reaction mixture was diluted with ethyl acetate, washed with water and then with saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was dissolved in tetrahydrofuran (5 mL). N,N′-Carbonyldiimidazole (115 mg) and then 1,8-diazabicyclo[5.4.0]undec-7-ene (108 mg) were added, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was diluted with ethyl acetate, washed with saturated aqueous potassium hydrogensulfate solution and then with saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography [eluent: methanol/ethyl acetate=5/95→30/70 (volume ratio)] and crystallized from acetonitrile to give the title compound as colorless crystals (108 mg, 31%).
Loading…